 |
|
|
| |
Real-World Cost-Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment-Naïve (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) in the United States (US)
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017
Shelby L. Corman1; Bruce Bacon2; Michael P. Curry3; Douglas T. Dieterich4;
Steven L. Flamm5; Yiling Jiang6; Kris V. Kowdley7; Scott Milligan8; Chizoba
Nwankwo9; Naoky C. Tsai10; Zobair M. Younossi11; Nezam H. Afdhal3
1Pharmerit International, Bethesda, MD, USA; 2Saint Louis University School of Medicine, St. Louis, MO, USA; 3Beth Israel Deaconess Medical
Center, Boston, MA, USA; 4Icahn School of Medicine at Mount Sinai, New York, NY, USA; 5Northwestern University Feinberg School of
Medicine, Chicago, IL, USA; 6Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, UK; 7Liver Care Network, Swedish Medical Center,
Seattle, WA, USA; 8Trio Health Analytics, La Jolla, CA, USA; 9Merck & Co., Inc., Kenilworth, NJ, USA; 10Queens Medical Center, University
of Hawaii, Honolulu, HI, USA; 11Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA.
|
| |
|
|
|
|
|
